UiPath stock remains a "Buy" given its revenue/ARR growth, strong retention, and moat. Here's what investors need to know.
Currently, PATH shares trade at a significant 40% discount to peers based on EV/Sales and EV/EBITDA multiples. The transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results